Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Jan;30(1):118-120.
doi: 10.3350/cmh.2023.0472. Epub 2023 Nov 14.

Letter regarding "Waiting for the changes after the adoption of steatotic liver disease"

Kuo Chao Yew  1 , Sunny H Wong  1   2 , Vincent Wai-Sun Wong  3   4 , Hazel H Oon  5
Affiliations
Comment

Letter regarding "Waiting for the changes after the adoption of steatotic liver disease"

Kuo Chao Yew et al. Clin Mol Hepatol. 2024 Jan.
No abstract available

Keywords: Alcohol; Fatty liver; Metabolic; NAFLD; Social policies.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

Kuo Chao Yew: speaker for Gilead Sciences and AbbVie, clinical investigator for AstraZeneca.

Sunny H. Wong: Advisory committee member for Groken Biosciences, Biocodex, and Aptorum Group Limited; speaker for Janssen and AstraZeneca.

Vincent W. Wong: advisory committee member for AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Intercept, Inventiva, Merck, Novo Nordisk, Pfizer, Sagimet Biosciences and TARGET Pharma Solutions; speaker for Abbott, AbbVie, Gilead Sciences, Novo Nordisk and Unilab. Received a research grant from Gilead Sciences and is a cofounder of Illuminatio Medical Technology.

Hazel H. Oon: speaker, advisory board member and researcher for AbbVie, Galderma, Janssen and Novartis. Clinical investigator for Pfizer, advisory board member for Amgen, speaker and advisory board member for Boehringer Ingelheim and Eli Lilly.

Comment in

Comment on

References

    1. Yoon EL, Jun DW. Waiting for the changes after the adoption of steatotic liver disease. Clin Mol Hepatol. 2023;29:844–850. - PMC - PubMed
    1. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023 Jun 24; doi: 10.1016/j.jhep.2023.06.003. doi: - DOI - PubMed
    1. Singal AK, Kwo P, Kwong A, Liangpunsakul S, Louvet A, Mandrekar P, et al. Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease. Hepatology. 2022;75:1026–1037. - PMC - PubMed
    1. Chan WMM, Yew YW, Theng TSC, Liew CF, Oon HH. Prevalence of metabolic syndrome in patients with psoriasis: a cross-sectional study in Singapore. Singapore Med J. 2020;61:194–199. - PMC - PubMed
    1. Song SJ, Lai JC, Wong GL, Wong VW, Yip TC. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2023 Aug 2; doi: 10.1016/j.jhep.2023.07.021. doi: - DOI - PubMed

LinkOut - more resources